Pfizer Says Off-Label Marketing FCA Suit Falls Short
Pfizer Inc. asked a Massachusetts federal court on Tuesday to dismiss a False Claims Act whistleblower suit alleging that it improperly promoted off-label use of a schizophrenia drug, saying that the...To view the full article, register now.
Already a subscriber? Click here to view full article